Dr. August Troendle is a physician, scientist, and the self-made founder and CEO of Medpace (NASDAQ: MEDP), a leading global Contract Research Organization (CRO). His background is rooted in the highest levels of medical science and regulatory affairs. He received his Medical Degree (M.D.) from the University of Maryland, School of Medicine, and later secured an MBA from Boston University, uniquely blending clinical expertise with business acumen.

His career began in the highly regulated sphere of government: from 1986 to 1987, Dr. Troendle served as a Medical Review Officer at the U.S. Food and Drug Administration (FDA). This experience provided him with a deep, insider's understanding of the rigorous process required to bring safe and effective drugs to market. He then moved to the pharmaceutical industry, working at Sandoz (now Novartis) until 1992, where he specialized in the clinical development of lipid-altering agents. This rare combination of regulatory, clinical, and corporate experience inspired his vision for Medpace.

Dr. August Troendle founded Medpace in Cincinnati, Ohio, in 1992, with a clear mission: to offer a more innovative, high-science, and efficient way to conduct clinical trials. He envisioned Medpace as a full-service, therapeutic-area-specific CRO, acting as a partner rather than just a service provider to biopharmaceutical sponsors. This vertical integration of clinical expertise and trial execution streamlined the complex process of drug development.

Under his leadership as CEO and Chairman, Medpace has grown organically into a global giant with thousands of associates across over 40 countries. Troendle's background as a medical doctor sets him apart, as he understands the human stories and the ethical gravity behind the trials his company manages. He has guided Medpace through its growth and public listing, cementing his personal fortune and the company's reputation for scientific rigor, which is critical to accelerating the development of life-saving medical therapeutics worldwide.

Dr. Troendle’s social impact is deeply embedded in the mission of Medpace: accelerating the global development of safe and effective medical therapeutics. By improving the efficiency and quality of clinical trials, his company helps expedite the delivery of life-saving drugs to millions of patients.

His medical background ensures a continuous focus on the ethical and human dimensions of drug development. His philanthropy supports medical and scientific research, leveraging his M.D. and MBA to ensure that capital is directed toward meaningful, high-impact scientific endeavors for the betterment of human health globally.

Dr. August Troendle projects the highly professional and disciplined style of a scientist-turned-CEO. His attire is consistently formal, favoring tailored suits and a classic business presentation suitable for medical conferences and corporate boardrooms. His aesthetic is one of sobriety and intellectual rigor, reflecting the ethical demands of the pharmaceutical research industry.

Residing in Palo Alto, California, his luxury is defined by the security of his multi-billion dollar Medpace stake and the intellectual satisfaction of leading a company that profoundly impacts global health. His life is dedicated to the intersection of science and commerce, ensuring that his technical expertise continues to drive the future of clinical research.